Pfizer India Announces Robust Dividends and Q4 Financial Results
Pfizer India has released its Q4 financial results, showing significant growth. The company's revenue increased by 8.23% to ₹592.00 crore, while EBITDA grew by 20.63% to ₹228.00 crore. Net profit surged by 84.92% to ₹331.00 crore, partly due to an exceptional item of ₹173.00 crore. The EBITDA margin improved by 378 basis points to 38.43%. Pfizer India also announced a total dividend of ₹165.00 per share, including a final dividend of ₹35.00 and special dividends of ₹100.00 and ₹30.00. Despite strong Q4 results, annual figures showed a moderate decline in revenue and profitability compared to the previous fiscal year.
24Feb 25
Pfizer Ltd Shares Surge 8% on Marketing Deal with Mylan, Despite Q3 Profit Dip
Pfizer Ltd's shares rose over 8% following a 5-year sales and marketing agreement with Mylan Pharmaceuticals for CNS therapy brands Ativan and Pacitane in India. This surge occurred despite a slight decline in Q3 FY2024 results, with revenue down 0.51% to ₹580.8 crore and net profit falling 1.85% to ₹127.6 crore year-on-year. The partnership aims to leverage Mylan's marketing network to boost sales of these CNS medications in the Indian market.
21Feb 25
Pfizer Ltd Inks Marketing and Supply Deal with Mylan for Two Key Brands
Pfizer Limited has entered a 5-year marketing and supply agreement with Mylan Pharmaceuticals for two established brands, Ativan and Pacitane, in the Indian market. The strategic partnership aims to leverage Mylan's expertise in the Central Nervous System (CNS) therapy area, enhancing distribution and specialist engagement. This collaboration is expected to boost the in-clinic presence of Pfizer's products without significant additional investment.